These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11585252)

  • 1. p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases.
    Korshunov A; Golanov A; Timirgaz V
    Acta Neuropathol; 2001 Sep; 102(3):271-7. PubMed ID: 11585252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical markers for prognosis of ependymal neoplasms.
    Korshunov A; Golanov A; Timirgaz V
    J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
    Korshunov A; Golanov A; Timirgaz V
    J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas.
    Kumamoto H; Izutsu T; Ohki K; Takahashi N; Ooya K
    J Oral Pathol Med; 2004 May; 33(5):292-9. PubMed ID: 15078490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.
    Verstegen MJ; Leenstra DT; Ijlst-Keizers H; Bosch DA
    J Neurooncol; 2002 Jan; 56(1):21-8. PubMed ID: 11949823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
    Eymin B; Gazzeri S; Brambilla C; Brambilla E
    Oncogene; 2002 Apr; 21(17):2750-61. PubMed ID: 11965548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 Pathway dysfunction in primary childhood ependymomas.
    Gaspar N; Grill J; Geoerger B; Lellouch-Tubiana A; Michalowski MB; Vassal G
    Pediatr Blood Cancer; 2006 May; 46(5):604-13. PubMed ID: 16086408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index.
    Schröder R; Ploner C; Ernestus RI
    Neurosurg Rev; 1993; 16(2):145-50. PubMed ID: 8345908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
    Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
    Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
    Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
    Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
    Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
    Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
    Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
    Suri VS; Tatke M; Singh D; Sharma A
    Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification and overexpression of mdm2 gene in ependymomas.
    Suzuki SO; Iwaki T
    Mod Pathol; 2000 May; 13(5):548-53. PubMed ID: 10824927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases.
    Korshunov A; Sycheva R; Timirgaz V; Golanov A
    J Neurooncol; 1999; 45(3):219-27. PubMed ID: 10845392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome.
    Korshunov A; Golanov A
    Arch Pathol Lab Med; 2002 Jan; 126(1):42-8. PubMed ID: 11800646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
    Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
    Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.
    Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J
    Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.